THDB(SH:600867) Shang Hai Zheng Quan Bao·2026-01-15 17:54Group 1 - The core announcement is about the appointment of two new vice presidents, Guandong Liang and Fan Pu, at Tonghua Dongbao Pharmaceutical Co., Ltd. Their terms will last until the end of the current board's tenure [1][3] - Guandong Liang has extensive experience in the pharmaceutical industry, having held various positions in companies such as Shanghai Hengrui Medicine Co., Ltd. and Beijing Xuzheng Innovation Drug Research Institute [4][5] - Fan Pu has a strong background in finance, previously serving as a senior manager at China Resources Group and as CFO at Yuekang Pharmaceutical Group [4][6] Group 2 - The announcement also includes details about the share pledge and re-pledge by the controlling shareholder, Dongbao Industrial Group, which holds 641,362,975 shares, accounting for 32.75% of the total shares [8][9] - Dongbao Group has pledged 562,439,472 shares, which is 87.69% of their holdings and 28.72% of the total shares of the company [8][9] - The funds from the share pledge are primarily intended to supplement working capital, with no significant asset restructuring or performance compensation involved [10][12] Group 3 - Dongbao Group has upcoming share pledges due within the next six months and one year, totaling 98,000,000 shares and 115,500,000 shares respectively, with corresponding financing amounts of 39,500 million and 49,500 million [12][13] - The company asserts that the share pledges will not impact its operations or governance, and there are no performance compensation obligations to fulfill [12][18] - Dongbao Group's financial health is under scrutiny, with a high debt ratio and low liquidity ratios, but it is expected that ongoing projects will eventually improve cash flow [16][18]